Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy
AssigneeThe Johns Hopkins University
InventorsJordan J. Green, Martin G. Pomper, Camila Gadens Zamboni, Hannah Vaughan, Il Minn
Life of this patent
Estimating the term…
Abstract
A DNA plasmid useful for diagnostic and therapeutic gene therapy is disclosed. Improvements to gene therapy methods known in the art are provided to ensure cancer-targeting, high efficacy, and long durability of expression. The DNA plasmid is combined with compositions of polymeric nanoparticles for non-viral gene therapy to treat cancer, including hepatocellular carcinoma and prostate cancer.
Claims35
A nucleic acid molecule comprising a nucleic acid sequence encoding a mutant thymidine kinase (TK) protein operatively linked to an alpha-fetoprotein (AFP) gene promoter, wherein the AFP gene promoter lacks CpG dinucleotides.
An isolated nucleic acid sequence comprising an alpha-fetoprotein (AFP) gene promoter which lacks CpG dinucleotides.
Dependencies are inferred from the claim text.